Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689792 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17778888 | 0.93 | PIM1 (0.38) | MTORJAK2MAPK1 | |
| SCHEMBL19689656 | 0.90 | WNT3A (0.43) | MTORSYKMAPK1 | |
| SCHEMBL19706688 | 0.90 | WNT3A (0.43) | MTORSYKMAPK1 | |
| SCHEMBL17768176 | 0.88 | IDH1 (0.34) | MTORIRAK4JAK2MAPK1 | |
| SCHEMBL17778323 | 0.88 | KARS1 (0.40) | MTORSYKMAPK1 | |
| SCHEMBL16754282 | 0.88 | KARS1 (0.40) | MTORSYKMAPK1 | |
| SCHEMBL19689817 | 0.87 | WNT3A (0.36) | MTORMAPK1 | |
| SCHEMBL17768095 | 0.86 | ABL1 (0.37) | MTORIRAK4MAPK1 | |
| SCHEMBL17768178 | 0.86 | ABL1 (0.37) | MTORIRAK4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PSEN1 1105/4885PSEN2 1731/4885APH1B 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.